Govt cancels licenses of 18 pharma companies for manufacturing spurious medicines

Published On 2023-03-29 13:00 GMT   |   Update On 2023-03-29 13:00 GMT
Advertisement

Cracking a whip, the Union Government has cancelled the license of 18 pharma companies for producing spurious and adulterated drugs, while 26 pharma firms have been issued show-cause notice.

This comes in the backdrop of a massive nationwide crackdown on pharma companies amid reports of spurious drugs from India being sold abroad.

The Drugs Controller General of India (DCGI) had conducted inspection on 76 pharmaceutical companies. The surprise inspections were conducted by central and state teams. A majority of the companies are from Himachal Pradesh (70), followed by Uttarakhand (45) and Madhya Pradesh (23).

Advertisement

For more details, check out the link given below:

Massive Crackdown Against Spurious Drugs: License Of 18 Pharma Firms Cancelled, 26 Issued Show Cause Notice

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News